Genflow Advances SIRT6 Longevity Pipeline as Funding and Canine Trial Progress Bolster Position

Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an update.

Genflow Biosciences reported significant operational progress in 2025, highlighting its canine SLAB trial in aged beagles, which advanced without safety issues and is expected to complete by July 2026, and early partnering talks with major animal health companies to commercialise its SIRT6-based therapies. In human health, the company advanced its MASH candidate GF-1002 toward clinical readiness with substantial non-dilutive funding from the Wallonia region, launched a glaucoma programme with IRIS Pharma, shifted its delivery technology from AAV to LNP/mRNA platforms, strengthened global IP around its SIRT6 patents and bolstered its balance sheet through grants and equity raises while remaining debt-free, reinforcing its position in the emerging longevity sector.

Spark’s Take on GENF Stock

According to Spark, TipRanks’ AI Analyst, GENF is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.

To see Spark’s full report on GENF stock, click here.

More about Genflow Biosciences Plc

Genflow Biosciences Plc is a UK-based biotechnology company focused on longevity and developing gene therapies to counteract aging and age-related diseases. The company, the first longevity biotech listed in Europe, operates human and animal health divisions built around its proprietary SIRT6 centenarian-based gene therapy platform, targeting conditions such as MASH, sarcopenia, Werner syndrome and ophthalmic diseases.

Average Trading Volume: 2,725,012

Technical Sentiment Signal: Buy

Current Market Cap: £15M

For detailed information about GENF stock, go to TipRanks’ Stock Analysis page.